In this context, we had reported the anecdotal observation that the extent of dynamic adhesion of peripheral blood CD4+ T cells from IBD patients to the α4β7 ligand mucosal vascular addressin cell adhesion molecule (MAdCAM-)1 in this assay before initiation of vedolizumab treatment seemed to correlate with subsequent clinical response to therapy. Here, MADCAM1 is linked to inflammatory bowel disease.